Soleno Therapeutics (SLNO) Shares Outstanding (Diluted Average) (2014 - 2026)

Soleno Therapeutics (SLNO) has 9 years of Shares Outstanding (Diluted Average) data on file, last reported at $53.1 million in Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $53.1 million, up 14.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $53.1 million (up 14.92% YoY), and the FY2025 annual result was $52.4 million, up 30.39% from the prior year.
• Shares Outstanding (Diluted Average) grew to $53.1 million in Q1 2026 per SLNO's latest filing, from $52.4 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $53.1 million in Q1 2026 and troughed at $5.3 million in Q1 2022.
• A 5-year average of $27.1 million and a median of $26.4 million in 2023 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Diluted Average) plunged 90.79% in 2022, then soared 288.72% in 2024.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $8.4 million in 2022, then soared by 96.4% to $16.5 million in 2023, then surged by 143.61% to $40.2 million in 2024, then soared by 30.39% to $52.4 million in 2025, then gained by 1.3% to $53.1 million in 2026.
• Business Quant data shows SLNO's Shares Outstanding (Diluted Average) at $53.1 million in Q1 2026, $52.4 million in Q4 2025, and $50.5 million in Q2 2025.